Subscribe To

Price Alert Latest News Economic Calendar News

DGX / Quest Diagnostics (DGX) Q4 2022 Earnings Call Transcript

Quest Diagnostics Incorporated (NYSE:DGX ) Q4 2022 Earnings Conference Call February 2, 2023 8:30 AM ET Company Participants Jim Davis - President, Chief Executive Officer Sam Samad - Executive Vice President, Chief Financial Officer Shawn Bevec - Vice President, Investor Relations Conference Call Participants Ann Hynes - Mizuho Securities Patrick Donnelly - Citi Jack Meehan - Nephron Research AJ Rice - Credit Suisse Pito Chickering - Deutsche Bank Brian Tanquilut - Jefferies Kevin Caliendo - UBS Andrew Brackmann - William Blair Derik de Bruin - Bank of America Elizabeth Anderson - Evercore ISI Rachel Vatsndal - JP Morgan Operator Welcome to the Quest Diagnostics Fourth Quarter and Full Year 2002 conference call. At the request of the company, this call is being recorded. Read More

Demo Live Account See Partner Details

Content Topics

Quest

Diagnostics

DGX

2022

Earnings

Call

Transcript

Stock

Posted: Feb 2 2023, 11:42

Author Name: Seeking Alpha

DGX News

By Zacks Investment Research
October 24, 2023

Quest Diagnostics (DGX) Tops Q3 Earnings, Gross Margin Dips

Quest Diagnostics' (DGX) base business growth reflects the company's ongoing efforts to partner with health plans, hospitals and physicians amid a con

By Zacks Investment Research
October 24, 2023

Quest Diagnostics (DGX) Q3 Earnings and Revenues Beat Estimates

Quest Diagnostics (DGX) came out with quarterly earnings of $2.22 per share, beating the Zacks Consensus Estimate of $2.19 per share. This compares to

By Market Watch
October 24, 2023

Quest Diagnostics profit falls 12%, but beats estimate

Quest Diagnostics Inc. DGX, -1.84% said Tuesday its third-quarter profit dropped by 12.2% to $225 million, or $1.96 a share, from $256 million, or $2.

By Zacks Investment Research
October 19, 2023

Quest Diagnostics (DGX) to Post Q3 Earnings: What's in Store?

Quest Diagnostics (DGX) third-quarter 2023 results are likely to reflect continued strength in the base business.

By Zacks Investment Research
October 18, 2023

Quest Diagnostics (DGX) Gains From New Alliances Amid FX Woes

Quest Diagnostics' (DGX) recent acquisition of New York-Presbyterian's outreach assets adds to volume growth within Physician Lab Services.

By Zacks Investment Research
October 6, 2023

Quest Diagnostics (DGX) to Boost Lab Services With New Pact

Quest Diagnostics (DGX) latest deal will boost dialysis laboratory testing and reduce the laboratory costs of dialysis programs for ESRD patients.

By PRNewsWire
October 4, 2023

Quest Diagnostics to Release Third Quarter 2023 Financial Results on October 24, 2023

SECAUCUS, N.J. , Oct. 4, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information servi

By Zacks Investment Research
October 2, 2023

Should Value Investors Buy Quest Diagnostics (DGX) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Neverthe

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.